{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T09:23:15Z","timestamp":1773739395826,"version":"3.50.1"},"reference-count":103,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2006,6,1]],"date-time":"2006-06-01T00:00:00Z","timestamp":1149120000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nervenarzt"],"published-print":{"date-parts":[[2006,6]]},"DOI":"10.1007\/s00115-006-2080-4","type":"journal-article","created":{"date-parts":[[2006,3,30]],"date-time":"2006-03-30T13:28:05Z","timestamp":1143725285000},"page":"682-693","source":"Crossref","is-referenced-by-count":11,"title":["Medikamenteninduzierte Myopathien","Medically induced myopathia"],"prefix":"10.1007","volume":"77","author":[{"given":"J.","family":"Finsterer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"2080_CR1","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1517\/14740338.1.1.65","volume":"1","author":"Bannwarth","year":"2002","unstructured":"Bannwarth B (2002) Drug-induced myopathies. Expert Opin Drug Saf 1:65\u201370","journal-title":"Expert Opin Drug Saf"},{"key":"2080_CR2","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.ncl.2004.12.014","volume":"23","author":"Walsh","year":"2005","unstructured":"Walsh RJ, Amato AA (2005) Toxic myopathies. Neurol Clin 23:397\u2013428","journal-title":"Neurol Clin"},{"key":"2080_CR3","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1097\/01.md.0000188565.48918.41","volume":"84","author":"Melli","year":"2005","unstructured":"Melli G, Chaudhry V, Cornblath DR (2005) Rhabdomyolysis: an evaluation of 475 hospitalized patients. Medicine 84:377\u2013385","journal-title":"Medicine"},{"key":"2080_CR4","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0950-3579(05)80294-8","volume":"5","author":"Le","year":"1991","unstructured":"Le Quintrec JS, Le Quintrec JL (1991) Drug-induced myopathies. Baillieres Clin Rheumatol 5:21\u201338","journal-title":"Baillieres Clin Rheumatol"},{"key":"2080_CR5","doi-asserted-by":"crossref","unstructured":"Schoser BG, Pongratz D (2005) Lipid lowering drug and other toxic myopathies. Internist (Berl) 46:1198\u20131206","DOI":"10.1007\/s00108-005-1490-x"},{"key":"2080_CR6","first-page":"278","volume":"51","author":"Coquet","year":"2001","unstructured":"Coquet M, Bannwarth B, Henin D (2001) Drug-induced and toxic myopathies. Rev Prat 51:278\u2013283","journal-title":"Rev Prat"},{"key":"2080_CR7","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1159\/000088531","volume":"61","author":"Nasu","year":"2005","unstructured":"Nasu K, Sugano T, Yoshimatsu J et al. (2005) Rhabdomyolysis caused by tocolysis with oral ritodrine hydrochloride in a pregnant patient with myotonic dystrophy. Gynecol Obstet Invest 61:53\u201355","journal-title":"Gynecol Obstet Invest"},{"key":"2080_CR8","first-page":"E26","volume":"9","author":"Baker","year":"2005","unstructured":"Baker SK, Tarnopolsky MA (2005) Statin-associated neuromyotoxicity. Timely Top Med Cardiovasc Dis 9:E26","journal-title":"Timely Top Med Cardiovasc Dis"},{"key":"2080_CR9","first-page":"1855","volume":"26","author":"Franc","year":"1997","unstructured":"Franc S, Bruckert E, Giral P et al. (1997) Rhabdomyolysis in patients with preexisting myopathy, treated with antilipemic agents. Presse Med 26:1855\u20131858","journal-title":"Presse Med"},{"key":"2080_CR10","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1111\/j.1365-2796.2005.01515.x","volume":"258","author":"Voermans","year":"2005","unstructured":"Voermans NC, Lammens M, Wevers RA et al. (2005) Statin-disclosed acid maltase deficiency. J Intern Med 258:196\u2013197","journal-title":"J Intern Med"},{"key":"2080_CR11","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1007\/s00115-004-1837-x","volume":"76","author":"K","year":"2005","unstructured":"K\u00f6ller H, Neuhaus O, Schroeter M et al. (2005) Myopathies under therapy with lipid-lowering agents. Nervenarzt 76:212\u2013217","journal-title":"Nervenarzt"},{"key":"2080_CR12","first-page":"268","volume":"Klin","author":"Bruggemann","year":"1996","unstructured":"Bruggemann W, Herath H, Ferbert A (1996) Follow-up and immunologic findings in drug-induced myasthenia. Med Klin (Munich) 91:268\u2013271","journal-title":"Med"},{"key":"2080_CR13","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1097\/00002371-200207000-00009","volume":"25","author":"Fraenkel","year":"2002","unstructured":"Fraenkel PG, Rutkove SB, Matheson JK et al. (2002) Induction of myasthenia gravis, myositis, and insulin-dependent diabetes mellitus by high-dose interleukin-2 in a patient with renal cell cancer. J Immunother 25:373\u2013378","journal-title":"J Immunother"},{"key":"2080_CR14","first-page":"23","volume":"57","author":"Owczarek","year":"2005","unstructured":"Owczarek J, Jasinska M, Orszulak-Michalak D (2005) Drug-induced myopathies. An overview of the possible mechanisms. Pharmacol Rep 57:23\u201334","journal-title":"Pharmacol Rep"},{"key":"2080_CR15","doi-asserted-by":"crossref","unstructured":"Kanda F, Okuda S, Matsushita T et al. (2001) Steroid myopathy: pathogenesis and effects of growth hormone and insulin-like growth factor-I administration. Horm Res 56[Suppl\u00a01]:24\u201328","DOI":"10.1159\/000048130"},{"key":"2080_CR16","first-page":"554","volume":"51","author":"Kumar","year":"2003","unstructured":"Kumar S (2003) Steroid-induced myopathy following a single oral dose of prednisolone. Neurol India 51:554\u2013556","journal-title":"Neurol India"},{"key":"2080_CR17","doi-asserted-by":"crossref","first-page":"362","DOI":"10.12968\/hmed.2005.66.6.18414","volume":"66","author":"Adamson","year":"2005","unstructured":"Adamson R, Rambaran C, D\u2019Cruz DP (2005) Anabolic steroid-induced rhabdomyolysis. Hosp Med 66:362","journal-title":"Hosp Med"},{"key":"2080_CR18","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1345\/aph.1C095","volume":"36","author":"Polsonetti","year":"2002","unstructured":"Polsonetti BW, Joy SD, Laos LF (2002) Steroid-induced myopathy in the ICU. Ann Pharmacother 36:1741\u20131744","journal-title":"Ann Pharmacother"},{"key":"2080_CR19","doi-asserted-by":"crossref","unstructured":"Finsterer J, Sch\u00e4fer J, Reichmann H (2004) Muskelerkrankungen und Myasthenien. In: Stefan H, Mamoli B (Hrsg) Aktuelle Therapie in der Neurologie. Ecomed, Landsberg\/Lech","DOI":"10.1016\/B978-343723390-6.50064-4"},{"key":"2080_CR20","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1345\/aph.1D498","volume":"38","author":"Roten","year":"2004","unstructured":"Roten L, Schoenenberger RA, Krahenbuhl S et al. (2004) Rhabdomyolysis in association with simvastatin and amiodarone. Ann Pharmacother 38:978\u2013981","journal-title":"Ann Pharmacother"},{"key":"2080_CR21","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1097\/01213011-200506000-00007","volume":"15","author":"Wilke","year":"2005","unstructured":"Wilke RA, Moore JH, Burmester JK (2005) Relative impact of CYP3A genotype and concomitant medication on the severity of atorvastatin-induced muscle damage. Pharmacogenet Genomics 15:415\u2013421","journal-title":"Pharmacogenet Genomics"},{"key":"2080_CR22","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0378-4274(02)00010-3","volume":"128","author":"Hodel","year":"2002","unstructured":"Hodel C (2002) Myopathy and rhabdomyolysis with lipid-lowering drugs. Toxicol Lett 128:159\u2013168","journal-title":"Toxicol Lett"},{"key":"2080_CR23","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s00115-002-1445-6","volume":"74","author":"Finsterer","year":"2003","unstructured":"Finsterer J (2003) Fibrate and statine myopathy. Nervenarzt 74:115\u2013122","journal-title":"Nervenarzt"},{"key":"2080_CR24","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1111\/j.1468-1331.2005.01027.x","volume":"12","author":"Finsterer","year":"2005","unstructured":"Finsterer J, Stollberger C (2005) Myalgia, hyper-CK-aemia, and hypocoagulability in a patient under rosuvastatin and warfarin. Eur J Neurol 12:660","journal-title":"Eur J Neurol"},{"key":"2080_CR25","first-page":"640","volume":"16","author":"Mubhtar","year":"2005","unstructured":"Mubhtar RY, Reckless JP (2005) Statin-induced myositis: a commonly encountered or rare side effect? Curr Opin Lipidol 16:640\u2013647","journal-title":"Curr Opin Lipidol"},{"key":"2080_CR26","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.revmed.2003.10.013","volume":"25","author":"Fauchais","year":"2004","unstructured":"Fauchais AL, Iba Ba J, Maurage P et al. (2004) Polymyositis induced or associated with lipid-lowering drugs: five cases. Rev Med Interne 25:294\u2013298","journal-title":"Rev Med Interne"},{"key":"2080_CR27","doi-asserted-by":"crossref","first-page":"581","DOI":"10.7326\/0003-4819-137-7-200210010-00009","volume":"137","author":"Phillips","year":"2002","unstructured":"Phillips PS, Haas RH, Bannykh S et al. (2002) Scripps Mercy Clinical Research Center. Statin-associated myopathy with normal creatine kinase levels. Ann Intern Med 137:581\u2013585","journal-title":"Ann Intern Med"},{"key":"2080_CR28","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1001\/jama.289.13.1681","volume":"289","author":"Thompson","year":"2003","unstructured":"Thompson PD, Clarkson P, Karas RH (2003) Statin-associated myopathy. JAMA 289:1681\u20131690","journal-title":"JAMA"},{"key":"2080_CR29","first-page":"845","volume":"43","author":"Farswan","year":"2005","unstructured":"Farswan M, Rathod SP, Upaganlawar AB et al. (2005) Protective effect of coenzyme Q10 in simvastatin and gemfibrozil induced rhabdomyolysis in rats. Indian J Exp Biol 43:845\u2013848","journal-title":"Indian J Exp Biol"},{"key":"2080_CR30","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1124\/dmd.30.5.505","volume":"30","author":"Prueksaritanont","year":"2002","unstructured":"Prueksaritanont T, Subramanian R, Fang X et al. (2002) Glucuronidation of statins in animals and humans: a novel mechanism of statin lactonization. Drug Metab Dispos 30:505\u2013512","journal-title":"Drug Metab Dispos"},{"key":"2080_CR31","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/00000441-200504000-00009","volume":"329","author":"Morimoto","year":"2005","unstructured":"Morimoto S, Fujioka Y, Tsutsumi C et al. (2005) Mizoribine-induced rhabdomyolysis in a rheumatoid arthritis patient receiving bezafibrate treatment. Am J Med Sci 329:211\u2013213","journal-title":"Am J Med Sci"},{"key":"2080_CR32","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s11897-004-0002-y","volume":"1","author":"Bhatia","year":"2004","unstructured":"Bhatia GS, Lip GY (2004) Atrial fibrillation post-myocardial infarction: frequency, consequences, and management. Curr Heart Fail Rep 1:149\u2013155","journal-title":"Curr Heart Fail Rep"},{"key":"2080_CR33","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1093\/ajhp\/60.17.1791a","volume":"60","author":"de","year":"2003","unstructured":"de Denus S, Spinler SA (2003) Amiodarone\u2019s role in simvastatin-associated rhabdomyolysis. Am J Health Syst Pharm 60:1791","journal-title":"Am J Health Syst Pharm"},{"key":"2080_CR34","first-page":"368","volume":"42","author":"Kamaliah","year":"2001","unstructured":"Kamaliah MD, Sanjay LD (2001) Rhabdomyolysis and acute renal failure following a switchover of therapy between two fibric acid derivatives. Singapore Med J 42:368\u2013372","journal-title":"Singapore Med J"},{"key":"2080_CR35","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1002\/mus.20338","volume":"32","author":"Authier","year":"2005","unstructured":"Authier FJ, Chariot P, Gherardi RK (2005) Skeletal muscle involvement in human immunodeficiency virus (HIV)-infected patients in the era of highly active antiretroviral therapy (HAART). Muscle Nerve 32:247\u2013260","journal-title":"Muscle Nerve"},{"key":"2080_CR36","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2165\/00003495-199958010-00015","volume":"58","author":"Jarvis","year":"1999","unstructured":"Jarvis B, Faulds D (1999) Lamivudine. A review of its therapeutic potential in chronic hepatitis B. Drugs 58:101\u2013141","journal-title":"Drugs"},{"key":"2080_CR37","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1111\/j.1365-2044.2005.04208.x","volume":"60","author":"Fodale","year":"2005","unstructured":"Fodale V, Mazzeo A, Pratico C et al. (2005) Fatal exacerbation of peripheral neuropathy during lamivudine therapy: evidence for iatrogenic mitochondrial damage. Anaesthesia 60:806\u2013810","journal-title":"Anaesthesia"},{"key":"2080_CR38","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJM199004193221602","volume":"322","author":"Dalakas","year":"1990","unstructured":"Dalakas MC, Illa I, Pezeshkpour GH et al. (1990) Mitochondrial myopathy caused by long-term zidovudine therapy. N Engl J Med 322:1098\u20131105","journal-title":"N Engl J Med"},{"key":"2080_CR39","doi-asserted-by":"crossref","unstructured":"Miro O, Lopez S, Cardellach F et al. (2005) Mitochondrial studies in HAART-related lipodystrophy: from experimental hypothesis to clinical findings. Antivir Ther 10[Suppl\u00a02]:M73\u2013M81","DOI":"10.1177\/135965350501002S08"},{"key":"2080_CR40","first-page":"44","volume":"43","author":"Fujii","year":"2003","unstructured":"Fujii Y, Arimura Y, Takahashi N et al. (2003) A case of Behcet\u2019s disease associated with neuromyopathy induced by combination therapy with colchicine and cyclosporin. Ryumachi 43:44\u201350","journal-title":"Ryumachi"},{"key":"2080_CR41","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1097\/00000441-200012000-00007","volume":"320","author":"Kusus","year":"2000","unstructured":"Kusus M, Stapleton DD, Lertora JJ et al. (2000) Rhabdomyolysis and acute renal failure in a cardiac transplant recipient due to multiple drug interactions. Am J Med Sci 320:394\u2013397","journal-title":"Am J Med Sci"},{"key":"2080_CR42","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/BF02551424","volume":"29","author":"Locsey","year":"1997","unstructured":"Locsey L, Asztalos L, Kincses Z et al. (1997) Fluvastatin (Lescol) treatment of hyperlipidaemia in patients with renal transplants. Int Urol Nephrol 29:95\u2013106","journal-title":"Int Urol Nephrol"},{"key":"2080_CR43","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.ijcard.2003.11.019","volume":"99","author":"Sochman","year":"2005","unstructured":"Sochman J, Podzimkova M (2005) Not all statins are alike: induced rhabdomyolysis on changing from one statin to another one. Int J Cardiol 99:145\u2013146","journal-title":"Int J Cardiol"},{"key":"2080_CR44","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1046\/j.1365-2133.2001.04088.x","volume":"144","author":"Geilen","year":"2001","unstructured":"Geilen CC, Arnold M, Orfanos CE (2001) Mycophenolate mofetil as a systemic antipsoriatic agent: positive experience in 11 patients. Br J Dermatol 144:583\u2013586","journal-title":"Br J Dermatol"},{"key":"2080_CR45","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/s00347-002-0651-8","volume":"99","author":"Greiner","year":"2002","unstructured":"Greiner K, Varikkara M, Santiago C et al. (2002) Efficiency of mycophenolate mofetil in the treatment of intermediate and posterior uveitis. Ophthalmologe 99:691\u2013694","journal-title":"Ophthalmologe"},{"key":"2080_CR46","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1093\/ndt\/gfh199","volume":"19","author":"Piccoli","year":"2004","unstructured":"Piccoli GB, Rossetti M, Guarena C et al. (2004) Myalgia: an uncommon or underestimated side effect of mycophenolate mophetil after transplantation? Nephrol Dial Transplant 19:1940\u20131942","journal-title":"Nephrol Dial Transplant"},{"key":"2080_CR47","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1034\/j.1600-6143.2002.20909.x","volume":"2","author":"Hardinger","year":"2002","unstructured":"Hardinger KL, Wang CD, Schnitzler MA et al.(2002) Prospective, pilot, open-label, short-term study of conversion to leflunomide reverses chronic renal allograft dysfunction. Am J Transplant 2:867\u2013871","journal-title":"Am J Transplant"},{"key":"2080_CR48","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/j.1399-0012.1997.tb00843.x","volume":"11","author":"Neu","year":"1997","unstructured":"Neu AM, Furth SL, Case BW et al. (1997) Evaluation of neurotoxicity in pediatric renal transplant recipients treated with tacrolimus (FK506). Clin Transplant 11:412\u2013414","journal-title":"Clin Transplant"},{"key":"2080_CR49","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1159\/000074101","volume":"71","author":"Veroux","year":"2003","unstructured":"Veroux P, Veroux M, Puliatti C et al. (2003) Severe neurotoxicity in tacrolimus-treated living kidney transplantation in two cases. Urol Int 71:433\u2013434","journal-title":"Urol Int"},{"key":"2080_CR50","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1038\/sj.leu.2402868","volume":"17","author":"Shimazaki","year":"2003","unstructured":"Shimazaki C, Ochiai N, Uchida R et al. (2003) Intramuscular edema as a complication of treatment with imatinib. Leukemia 17:804\u2013805","journal-title":"Leukemia"},{"key":"2080_CR51","first-page":"940","volume":"98","author":"Gabrielli","year":"2003","unstructured":"Gabrielli M, Santarelli L, Serricchio M et al. (2003) Acute reversible rhabdomyolysis during interferon alpha2B therapy for hepatitis C. Am J Gastroenterol 98:940","journal-title":"Am J Gastroenterol"},{"key":"2080_CR52","first-page":"66","volume":"18","author":"Kumar","year":"2005","unstructured":"Kumar L, Gangadharan VP, Rao DR et al. (2005) Safety and efficacy of an indigenous recombinant interferon-alpha-2b in patients with chronic myelogenous leukaemia: results of a multicentre trial from India. Nat Med J India 18:66\u201370","journal-title":"Natl Med J India"},{"key":"2080_CR53","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1080\/09546630152607916","volume":"12","author":"Ozdag","year":"2001","unstructured":"Ozdag F, Akar A, Eroglu E et al. (2001) Acute rhabdomyolysis during the treatment of scleromyxedema with interferon alfa. J Dermatolog Treat 12:167\u2013169","journal-title":"J Dermatolog Treat"},{"key":"2080_CR54","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1097\/01.TP.0000090752.85709.9F","volume":"76","author":"Finsterer","year":"2003","unstructured":"Finsterer J, Kanzler M, Weinberger A (2003) Sirolimus myopathy. Transplantation 76:1773\u20131774","journal-title":"Transplantation"},{"key":"2080_CR55","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/00000441-200504000-00009","volume":"329","author":"Morimoto","year":"2005","unstructured":"Morimoto S, Fujioka Y, Tsutsumi C et al. (2005) Mizoribine-induced rhabdomyolysis in a rheumatoid arthritis patient receiving bezafibrate treatment. Am J Med Sci 329:211\u2013213","journal-title":"Am J Med Sci"},{"key":"2080_CR56","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1634\/theoncologist.9-3-271","volume":"9","author":"Guilhot","year":"2004","unstructured":"Guilhot F (2004) Indications for imatinib mesylate therapy and clinical management. Oncologist 9:271\u2013281","journal-title":"Oncologist"},{"key":"2080_CR57","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1592\/phco.24.17.1784.52334","volume":"24","author":"Wilbur","year":"2004","unstructured":"Wilbur K, Makowsky M (2004) Colchicine myotoxicity: case reports and literature review. Pharmacotherapy 24:1784\u20131792","journal-title":"Pharmacotherapy"},{"key":"2080_CR58","first-page":"785","volume":"57","author":"Sugie","year":"2005","unstructured":"Sugie M, Kuriki A, Arai D et al. (2005) A case report of acute neuromyopathy induced by concomitant use of colchicine and bezafibrate. No To Shinkei 57:785\u2013790","journal-title":"No To Shinkei"},{"key":"2080_CR59","first-page":"367","volume":"Klin","author":"Besser","year":"1994","unstructured":"Besser R, Treese N, Bohl J et al. (1994) Clinical, neurophysiologic and biopsy findings in neurotoxic amiodarone syndrome. Med Klin (Munich) 89:367\u2013372","journal-title":"Med"},{"key":"2080_CR60","first-page":"468","volume":"62","author":"Bonnet","year":"1995","unstructured":"Bonnet C, Zabraniecki L, Bertin P et al. (1995) Amiodarone-induced neuromyopathy mimicking polymyositis. Rev Rhum Engl Ed 62:468","journal-title":"Rev Rhum Engl Ed"},{"key":"2080_CR61","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1002\/mus.880120613","volume":"12","author":"Carella","year":"1989","unstructured":"Carella F (1989) Myopathy and accumulation of amiodarone. Muscle Nerve 12:514","journal-title":"Muscle Nerve"},{"key":"2080_CR62","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1111\/j.1445-5994.1989.tb00314.x","volume":"19","author":"Clouston","year":"1989","unstructured":"Clouston PD, Donnelly PE (1989) Acute necrotising myopathy associated with amiodarone therapy. Aust N Z J Med 19:483\u2013485","journal-title":"Aust N Z J Med"},{"key":"2080_CR63","first-page":"135","volume":"49","author":"Silva","year":"1997","unstructured":"Silva Oropeza E, Peralta Rosado HR, Valero Elizondo C et al. (1997) A case of amiodarone and neuromyopathy. Rev Invest Clin 49:135\u2013139","journal-title":"Rev Invest Clin"},{"key":"2080_CR64","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1002\/mus.880120613","volume":"12","author":"Carella","year":"1989","unstructured":"Carella F (1989) Myopathy and accumulation of amiodarone. Muscle Nerve 12:514","journal-title":"Muscle Nerve"},{"key":"2080_CR65","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/BF02333668","volume":"8","author":"Carella","year":"1987","unstructured":"Carella F, Riva E, Morandi L et al. (1987) Myopathy during amiodarone treatment: a case report. Ital J Neurol Sci 8:605\u2013608","journal-title":"Ital J Neurol Sci"},{"key":"2080_CR66","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/00115550-200407000-00007","volume":"29","author":"Zink","year":"2004","unstructured":"Zink W, Graf BM (2004) Local anesthetic myotoxicity. Reg Anesth Pain Med 29:333\u2013340","journal-title":"Reg Anesth Pain Med"},{"key":"2080_CR67","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1213\/01.ANE.0000155956.59842.0A","volume":"101","author":"Zink","year":"2005","unstructured":"Zink W, Bohl JR, Hacke N et al. (2005) The long term myotoxic effects of bupivacaine and ropivacaine after continuous peripheral nerve blocks. Anesth Analg 101:548\u2013554","journal-title":"Anesth Analg"},{"key":"2080_CR68","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1097\/01.wnf.0000165352.10841.21","volume":"28","author":"Finsterer","year":"2005","unstructured":"Finsterer J, Haberler C, Schmiedel J (2005) Deterioration of Kearns-Sayre syndrome following articaine administration for local anesthesia. Clin Neuropharmacol 28:148\u2013149","journal-title":"Clin Neuropharmacol"},{"key":"2080_CR69","first-page":"3672","volume":"167","author":"Hansen","year":"2005","unstructured":"Hansen TG (2005) Propofol infusion syndrome in children. Ugeskr Laeger 167:3672\u20133675","journal-title":"Ugeskr Laeger"},{"key":"2080_CR70","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S0736-4679(00)00162-1","volume":"18","author":"Weiner","year":"2000","unstructured":"Weiner AL, Vieira L, McKay CA et al. (2000) Ketamine abusers presenting to the emergency department: a case series. J Emerg Med 18:447\u2013451","journal-title":"J Emerg Med"},{"key":"2080_CR71","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1097\/00063110-200306000-00018","volume":"10","author":"Hadad","year":"2003","unstructured":"Hadad E, Weinbroum AA, Ben-Abraham R (2003) Drug-induced hyperthermia and muscle rigidity: a practical approach. Eur J Emerg Med 10:149\u2013154","journal-title":"Eur J Emerg Med"},{"key":"2080_CR72","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1097\/00131402-200212000-00004","volume":"4","author":"Finsterer","year":"2003","unstructured":"Finsterer J (2003) Current concepts in malignant hyperthermia. J Clin Neuromuscul Dis 4:64\u201374","journal-title":"J Clin Neuromuscul Dis"},{"key":"2080_CR73","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1053\/bean.2003.0272","volume":"17","author":"Kampe","year":"2003","unstructured":"Kampe S, Krombach JW, Diefenbach C (2003) Muscle relaxants. Best Pract Res Clin Anaesthesiol 17:137\u2013146","journal-title":"Best Pract Res Clin Anaesthesiol"},{"key":"2080_CR74","doi-asserted-by":"crossref","first-page":"1818S","DOI":"10.1093\/jn\/135.7.1818S","volume":"135","author":"Burnham","year":"2005","unstructured":"Burnham EL, Moss M, Ziegler TR (2005) Myopathies in critical illness: characterization and nutritional aspects. J Nutr 135:1818S\u20131823S","journal-title":"J Nutr"},{"key":"2080_CR75","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1097\/01.ccx.0000155357.24360.89","volume":"11","author":"Latronico","year":"2005","unstructured":"Latronico N, Peli E, Botteri M (2005) Critical illness myopathy and neuropathy. Curr Opin Crit Care 11:126\u2013132","journal-title":"Curr Opin Crit Care"},{"key":"2080_CR76","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1056\/NEJMe020180","volume":"348","author":"Hudson","year":"2003","unstructured":"Hudson LD, Lee CM (2003) Neuromuscular sequelae of critical illness. N Engl J Med 348:745\u2013747","journal-title":"N Engl J Med"},{"key":"2080_CR77","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.1097\/00003246-199911000-00036","volume":"27","author":"Hund","year":"1999","unstructured":"Hund E (1999) Myopathy in critically ill patients. Crit Care Med 27:2544\u20132547","journal-title":"Crit Care Med"},{"key":"2080_CR78","first-page":"131","volume":"52","author":"Khilnani","year":"2004","unstructured":"Khilnani GC, Bansal R (2004) Neuromuscular weakness in critically ill. J Assoc Physicians India 52:131\u2013136","journal-title":"J Assoc Physicians India"},{"key":"2080_CR79","doi-asserted-by":"crossref","first-page":"71","DOI":"10.7205\/MILMED.169.1.71","volume":"169","author":"Riggs","year":"2004","unstructured":"Riggs JE, Pandey HK, Schochet SS Jr (2004) Critical illness myopathy associated with hyperthyroidism. Mil Med 169:71\u201372","journal-title":"Mil Med"},{"key":"2080_CR80","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1097\/01.CCM.0000157969.46388.A2","volume":"33","author":"Bercker","year":"2005","unstructured":"Bercker S, Weber-Carstens S, Deja M et al. (2005) Critical illness polyneuropathy and myopathy in patients with acute respiratory distress syndrome. Crit Care Med 33:711\u2013715","journal-title":"Crit Care Med"},{"key":"2080_CR81","first-page":"474","volume":"25","author":"Al-Jumah","year":"2004","unstructured":"Al-Jumah MA, Awada AA, Al-Ayafi HA et al. (2004) Neuromuscular paralysis in the intensive care unit. Saudi Med J 25:474\u2013477","journal-title":"Saudi Med J"},{"key":"2080_CR82","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s00415-004-0272-z","volume":"251","author":"Friedrich","year":"2004","unstructured":"Friedrich O, Hund E, Weber C et al. (2004) Critical illness myopathy serum fractions affect membrane excitability and intracellular calcium release in mammalian skeletal muscle. J Neurol 251:53\u201365","journal-title":"J Neurol"},{"key":"2080_CR83","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s00415-004-0272-z","volume":"251","author":"Friedrich","year":"2004","unstructured":"Friedrich O, Hund E, Weber C et al. (2004) Critical illness myopathy serum fractions affect membrane excitability and intracellular calcium release in mammalian skeletal muscle. J Neurol 251:53\u201365","journal-title":"J Neurol"},{"key":"2080_CR84","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1016\/S0149-2918(04)80177-2","volume":"26","author":"Mohammadianpanah","year":"2004","unstructured":"Mohammadianpanah M, Omidvari S, Mosalaei A et al. (2004) Cisplatin-induced hypokalemic paralysis. Clin Ther 26:1320\u20131323","journal-title":"Clin Ther"},{"key":"2080_CR85","first-page":"523","volume":"255","author":"Ardavanis","year":"2005","unstructured":"Ardavanis AS, Ioannidis GN, Rigatos GA (2005) Acute myopathy in a patient with lung adenocarcinoma treated with gemcitabine and docetaxel. Anticancer Res 255:523\u2013525","journal-title":"Anticancer Res"},{"key":"2080_CR86","first-page":"534","volume":"128","author":"Maubec","year":"2001","unstructured":"Maubec E, Oberlin O, Belhadj K et al. (2001) Subcutaneous inflammatory edema induced by MINE chemotherapy. Ann Dermatol Venereol 128:534\u2013537","journal-title":"Ann Dermatol Venereol"},{"key":"2080_CR87","doi-asserted-by":"crossref","first-page":"4595","DOI":"10.1200\/JCO.2004.08.080","volume":"22","author":"Bezjak","year":"2004","unstructured":"Bezjak A, Tu D, Bacon M et al. (2004) Quality of life in ovarian cancer patients: comparison of paclitaxel plus cisplatin, with cyclophosphamide plus cisplatin in a randomized study. J Clin Oncol 22:4595\u20134603","journal-title":"J Clin Oncol"},{"key":"2080_CR88","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s00520-005-0885-5","volume":"14","author":"Oh","year":"2005","unstructured":"Oh DY, Kim JH, Kim DW et al. (2005) CPR or DNR? End-of-life decision in Korean cancer patients: a single center\u2019s experience. Support Care Cancer 14:103\u2013108","journal-title":"Support Care Cancer"},{"key":"2080_CR89","doi-asserted-by":"crossref","first-page":"333","DOI":"10.3816\/CBC.2002.n.036","volume":"3","author":"Smith","year":"2002","unstructured":"Smith RE, Anderson SJ, Brown A et al. (2002) Phase II trial of doxorubicin\/docetaxel\/cyclophosphamide for locally advanced and metastatic breast cancer: results from NSABP trial BP-58. Clin Breast Cancer 3:333\u2013340","journal-title":"Clin Breast Cancer"},{"key":"2080_CR90","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1093\/annonc\/mdi046","volume":"16","author":"Thongprasert","year":"2005","unstructured":"Thongprasert S, Napapan S, Charoentum C et al. (2005) Phase II study of gemcitabine and cisplatin as first-line chemotherapy in inoperable biliary tract carcinoma. Ann Oncol 16:279\u2013281","journal-title":"Ann Oncol"},{"key":"2080_CR91","first-page":"586","volume":"12","author":"Oskay","year":"2002","unstructured":"Oskay T, Kutluay L, Ozyilkan O (2002) Dermatomyositis-like eruption after long-term hydroxyurea therapy for polycythemia vera. Eur J Dermatol 12:586\u2013588","journal-title":"Eur J Dermatol"},{"key":"2080_CR92","first-page":"525","volume":"9","author":"Crayton","year":"1991","unstructured":"Crayton H, Bohlmann T, Sufit R et al. (1991) Drug induced polymyositis secondary to leuprolide acetate (Lupron) therapy for prostate carcinoma. Clin Exp Rheumatol 9:525\u2013528","journal-title":"Clin Exp Rheumatol"},{"key":"2080_CR93","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1046\/j.1532-5415.2002.50474.x","volume":"50","author":"Van","year":"2002","unstructured":"Van Gerpen JA, McKinley KL (2002) Leuprolide-induced myopathy. J Am Geriatr Soc 50:1746","journal-title":"J Am Geriatr Soc"},{"key":"2080_CR94","first-page":"650","volume":"27","author":"Terao","year":"1999","unstructured":"Terao T, Hori H, Nakamura J (1999) L-tryptophan-induced eosinophilia-myalgia syndrome, Chinese restaurant syndrome. Ryoikibetsu Shokogun Shirizu 27:650\u2013653","journal-title":"Ryoikibetsu Shokogun Shirizu"},{"key":"2080_CR95","first-page":"1784","volume":"23","author":"Sullivan","year":"1996","unstructured":"Sullivan EA, Staehling N, Philen RM (1996) Eosinophilia-myalgia syndrome among the non-L-tryptophan users and pre-epidemic cases. J Rheumatol 23:1784\u20131787","journal-title":"J Rheumatol"},{"key":"2080_CR96","first-page":"538","volume":"37","author":"Haas","year":"2003","unstructured":"Haas CE, Magram Y, Mishra A (2003) Rhabdomyolysis and acute renal failure following an ethanol and diphenhydramine overdose. Ann Pharmacother 37:538\u2013542","journal-title":"Rhabdomyolysis and acute renal failure following an ethanol and diphenhydramine overdose Ann Pharmacother"},{"key":"2080_CR97","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1177\/194589240501900413","volume":"19","author":"O-Lee","year":"2005","unstructured":"O-Lee T, Stewart CE 4th, Seery L et al. (2005) Fluoroquinolone-induced arthralgia and myalgia in the treatment of sinusitis. Am J Rhinol 19:395\u2013399","journal-title":"Am J Rhinol"},{"key":"2080_CR98","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1592\/phco.23.2.159.32078","volume":"23","author":"Carver","year":"2003","unstructured":"Carver PL, Whang E, VandenBussche HL et al. (2003) Risk factors for arthralgias or myalgias associated with quinupristin-dalfopristin therapy. Pharmacotherapy 23:159\u2013164","journal-title":"Pharmacotherapy"},{"key":"2080_CR99","first-page":"514","volume":"30","author":"Matsuda","year":"2002","unstructured":"Matsuda Y, Nagayoshi Y, Kirihara N (2002) Rhabdomyolysis during prolonged intravenous tocolytic therapy. J Perinat Med 30:514\u2013516","journal-title":"J Perinat Med"},{"key":"2080_CR100","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s00115-004-1847-8","volume":"76","author":"Schara","year":"2005","unstructured":"Schara U, Mortier W (2005) Neuromuscular diseases 2: muscular dystrophies (MD). Nervenarzt 76:219\u2013237","journal-title":"Nervenarzt"},{"key":"2080_CR101","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1023\/A:1011672304666","volume":"26","author":"Wakata","year":"2001","unstructured":"Wakata N, Sugimoto H, Iguchi H et al. (2001) Bupivacaine hydrochloride induces muscle fiber necrosis and hydroxyl radical formation-dimethyl sulphoxide reduces hydroxyl radical formation. Neurochem Res 26:841\u2013844","journal-title":"Neurochem Res"},{"key":"2080_CR102","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1177\/096032719601501004","volume":"15","author":"Jouglard","year":"1996","unstructured":"Jouglard J, Kozak-Ribbens G, de Haro L et al. (1996) Research into individual predisposition to develop acute rhabdomyolysis attributed to fenoverine. Hum Exp Toxicol 15:815\u2013820","journal-title":"Hum Exp Toxicol"},{"key":"2080_CR103","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S0960-8966(01)00228-0","volume":"11","author":"Kottlors","year":"2001","unstructured":"Kottlors M, Jaksch M, Ketelsen UP et al. (2001) Valproic acid triggers acute rhabdomyolysis in a patient with carnitine palmitoyltransferase type II deficiency. Neuromuscul Disord 11:757\u2013759","journal-title":"Neuromuscul Disord"}],"container-title":["Der Nervenarzt"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-006-2080-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00115-006-2080-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-006-2080-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T05:43:12Z","timestamp":1736314992000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00115-006-2080-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,6]]},"references-count":103,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2006,6]]}},"alternative-id":["2080"],"URL":"https:\/\/doi.org\/10.1007\/s00115-006-2080-4","relation":{},"ISSN":["0028-2804","1433-0407"],"issn-type":[{"value":"0028-2804","type":"print"},{"value":"1433-0407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,6]]}}}